News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
New pathobiology studies look to accelerate RECOVER’s progress
The next phase of RECOVER’s pathobiology studies will focus on discoveries that can more immediately inform efforts to diagnose, prevent, and treat Long COVID.
Feature
186 Results
186 Results
RECOVER-TLC to discuss status of Long COVID clinical trials at annual workshop
Registration is open for the third annual RECOVER-TLC Workshop, where researchers, clinicians, people living with Long COVID, and advocates will discuss the latest clinical trial updates and the future of Long COVID research.
Feature
R3 Seminar Recap: Growing up with Long COVID—Risk factors and school impacts
Findings from RECOVER’s pediatric observational study show that Long COVID can affect children’s health and daily lives in different ways. During the September 15, 2026, RECOVER Research Review (R3) Seminar, researchers Rachel Gross, MD, MS; Kay Rhee, MD, MSc, MA; and Harrison Reeder, PhD, shared findings on Long COVID symptoms in children, factors that may increase Long COVID risk, and how the condition can affect learning and social development. RECOVER Patient and Caregiver Representative Ann Wallace, PhD, and Caregiver Representative Laura Covington also shared their families’ experiences navigating Long COVID and seeking support.
R3 Seminar Recap
RECOVER charts progress toward better understanding of different autonomic symptoms
During the next phase of the adult observational study, RECOVER researchers will continue investigating the causes of autonomic dysfunction, with symptoms such as dizziness, rapid heart rate, and extreme fatigue.
Feature
RECOVER Research Update: September 2026
RECOVER researchers continue to publish findings that could help scientists, doctors, patients, and caregivers navigate the complexities of Long COVID.
Research Update
RECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for Long COVID
RECOVER researchers conducted a clinical trial to test whether PAXLOVID, an antiviral drug, could reduce Long COVID symptoms when taken for 15 or 25 days. The study enrolled 959 adults with Long COVID at 69 sites across the US.
News Release
RECOVER to launch next phase of pediatric observational study
In early 2027, RECOVER will launch the next phase of its pediatric study, following more than 4,300 children, teens, and young adults over 2 years to learn how Long COVID changes as they grow up.
Feature
Biosamples from RECOVER clinical trials offer expanded opportunities for Long COVID research
Biosamples collected during RECOVER clinical trials can provide valuable information about how people’s bodies respond to treatment. Researchers who receive funding through a new research opportunity can now access these samples.
Feature
RECOVER Representatives create resources for people living with Long COVID
Drawing on lived experience, RECOVER Representatives created 4 new resources to help people with Long COVID track symptoms, navigate work, find mental health support, and access financial assistance.
Feature